Freshly funded: Congratulations to the CINERGY Team

The CDTRP wishes to congratulate the CINERGY team, led by Fréderick D’Aragon and Maureen Meade, on their funding received from CIHR 2020 Fall Competition.

We asked them a few questions about the process:

How has the CDTRP contributed to this work?

The CDTRP has supported the CINERGY study since it’s inception. The national integrated research structure of the CDTRP has provided unique opportunities for donation and transplant researchers across Canada to connect with one another, brainstorm, and collaborate on research as never before. Regular Theme meetings provide opportunities for high-level scientific review and input from seasoned clinicians and researchers. The uniquely strong Patient, Family and Donor program within the CDTRP allows for input from these key stakeholders in donation and transplant research, with respect to study design, ethical issues related to research consent, and important considerations about study outcomes. The CDTRP Innovation Grant funding has supported qualitative research along the way to enhance understanding of the views of transplant recipients with respect to their roles as participants in clinical research involving organ donors. In so many ways, the CDTRP has been a staunch supporter of innovation in organ donor care in the ICU.

How has the CDTRP helped with the funding application?

Recent funding success may not have been possible without specific support from the CDTRP. The administrative leads helped to introduce this work and garner letters of support from almost every organ transplant program in Ontario and Quebec. Then, the CDTRP provided their own informed and strategic letter of support. They have committed to providing real and virtual spaces for ongoing investigator meetings, as well as financial support for our patient and donor family partners in this exciting endeavour, now funded by the Canadian Institutes for Health Research.

CINERGY Lay Abstract

In Canada, most life-saving transplants involve vital organs from deceased organ donors. When organs are removed from organ donors, they are transported with great care to transplant centres in other hospitals, or cities, and even distant provinces. Any interval in time in which a donated organ is preserved without blood circulation may result in organ injury. The time without blood flow can cause organ injury and the re-establishment of blood flow during transplantation may lead to severe injury, called ischemia reperfusion injury, or IR injury. IR injury threatens the viability of organ transplants in the short term, and the long term. Several treatments for transplant recipients aim to reduce the risk of IR injury.  Similarly, there are treatments for the organ, itself, before transplant, that aim to mitigate IR injury. There are no treatments, however, provided to organ donors with a view to purpose of reducing IR jury and improving the health of organ transplant recipients. The CINERGY Pilot Trial, in Ontario and Quebec, will test the feasibility of a future national study that tests a drug for administered to organ donors to reduce IR injury in organ recipients. The drug is tacrolimus, a common transplant medication that has never been provided to organ donors. However, animal studies consistently suggest that the “preconditioning” of organ donors with tacrolimus will improve transplant function.